Imagine if we could spot liver damage like a tiny leak in a pipe before the whole system bursts. Right now, most people only find out they have liver disease when it's too late to fix. This project uses blood tests and AI to catch the problem early, allowing doctors to reverse the damage before it becomes permanent.
Liver disease often remains undetected until it reaches irreversible stages like cirrhosis or cancer, leading to 300,000 deaths annually in Europe. Current detection methods are either too late or not scalable for population-wide screening.
An AI-powered screening platform that uses commercial biomarkers to detect early-stage liver fibrosis in asymptomatic individuals.
If you are a diagnostic company dealing with low adoption of liver screening — this project developed a biomarker-based platform that uses AI to identify fibrosis. It leverages data from 100,000 participants to ensure high accuracy for population-wide screening.
If you are a pharma company dealing with difficulty identifying early-stage patients for clinical trials — this project developed a screening methodology to detect asymptomatic fibrosis. This allows for the targeting of personalized therapeutic interventions to halt disease progression.
If you are an AI developer dealing with a lack of high-quality clinical datasets for liver disease — this project developed an AI-driven diagnosis tool validated against 24,000 participant samples. This provides a scalable model for personalized early diagnosis.
Based on available project data, specific pricing is not mentioned, but the project includes a cost-effectiveness analysis to evaluate its economic impact on healthcare systems.
Yes, the project is designed for population screening across Europe and includes a validation study involving 100,000 subjects across 6 representative countries.
Based on available project data, specific licensing terms are not provided, but the consortium includes 11 industry partners, including major companies like Roche and Siemens Healthineers.
The project runs from March 2024 to February 2030, with the initial measurement phase of 24,000 samples expected to be completed by April 2025.
The platform integrates commercial biomarkers from providers like Roche and Siemens Healthineers and uses AI to shift diagnosis from late-stage to early screening.
The consortium is highly commercially oriented with a 34% industry ratio, comprising 11 industry partners including global leaders like Roche and Siemens Healthineers. With 32 partners across 13 countries, the group balances academic research (10 universities) with practical implementation expertise from SMEs and public health professionals, ensuring the resulting AI platform is compatible with existing diagnostic hardware.
Contact Fundacio de Recerca Clinica Barcelona-IDIBAPS
Contact us to explore licensing opportunities for the AI-driven liver screening platform.
